参考文献

[1]WHO. The top 10 causes of death. [EB/OL]. (2018-05-24）[2020-03-20]. http://www.who.int/mediacentre/factsheets/fs310/en/

[2]陈伟伟，高润霖，刘力生.2015年中国心血管病报告[J].中国循环杂志，2016，31（6）：521-528.

[3]MESCHIA J F, BUSHNELL C, BODEN-AB, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2014, 45（12）: 3754-3832.

[4]BIBBINS-DOMINGO K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement[J]. Ann Intern Med, 2016, 164（12）: 836-845.

[5]PIEPOLI M F, HOES A W, AGEWALL S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts）developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR）[J]. Eur Heart J, 2016, 37（29）: 2315-2381.

[6]YANG X, LI J, HU D, et al. Predicting the ten-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project[J]. Circulation, 2016, 134（19）: 1430.

[7]BONACA M P, BHATT D L, COHEN M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med, 2015, 372（19）: 1791-1800.

[8]GWON H C, HAHN J Y, PARK K W, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience/Promus versus cypher to reduce late loss after stenting（EXCELLENT) randomized, multicenter study[J]. Circulation, 2012, 125（3）: 505-513.

[9]COLLET J P, CUISSET T, RANGE G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting[J]. N Engl J Med, 2012, 367（22）: 2100-2109.

[10]COLOMBO A, CHIEFFO A, FRASHERI A, et al. Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial[J]. J Am Coll Cardiol, 2014, 64（20）: 2086-2097.

[11]SCHULZ-SCHUPKE S, BYRNE R A, TEN B J, et al. ISAR-SAFE: a randomized, double-blind, placebocontrolled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting[J]. Eur Heart J, 2015, 36（20）: 1252-1263.

[12]GILARD M, BARRAGAN P, NORYANI A A, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial[J]. J Am Coll Cardiol, 2015, 65（8）: 777-786.

[13]GARRATT K N, WEAVER W D, JENKINS R G, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberte paclitaxel-eluting coronary stent placement[J]. Circulation, 2015, 131（1）: 62-73.

[14]MAURI L, KEREIAKES D J, YEH R W, et al. Twelve or 30 months of dual antiplatelet therapy after drugeluting stents[J]. N Engl J Med, 2014, 371（23）: 2155-2166.

[15]GIUSTINO G, BABER U, SARTORI S, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials[J]. J Am Coll Cardiol, 2015, 65（13）: 1298-1310.

[16]LEVINE GN, BATES ER, BITTL JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery[J]. Circulation, 2016, 134（10）: e123-e155.

[17]LANDRAY M J, HAYNES R, HOPEWELL J C, et al. Effects of extended-release niacin with laropiprant in high-risk patients[J]. N Engl J Med, 2014, 371（3）: 203-212.

[18]CANNON C P, BLAZING M A, GIUGLIANO R P, et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med, 2015, 372（25）: 2387-2397.

[19]诸骏仁，高润霖，赵水平，等.中国成人血脂异常防治指南（2016年修订版）[J].中国循环杂志，2016，31（10）：937-953.

[20]WALD D S, MORRIS J K, WALD N J, et al. Randomized trial of preventive angioplasty in myocardial infarction[J]. N Engl J Med, 2013, 369（12）: 1115-1123.

[21]GERSHLICK A H, KHAN J N, KELLY D J, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial[J]. J Am Coll Cardiol, 2015, 65（10）: 963-972.

[22]ENGSTROM T, KELBAEK H, HELQVIST S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease（DANAMI-3-PRIMULTI）: an open-label, randomised controlled trial[J]. Lancet, 2015, 386（9994）: 665-671.

[23]HLINOMAZ O, GROCH L, POLOKOVÁK. Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial[R/OL]. http://sbhci.org.br/wpcontent/uploads/2015/05/PRAGUE-13-Trial.pdf.2015.

[24]SARATHY K, NAGARAJA V, KAPUR A, et al. Target-vessel versus multivessel revascularisation in ST-elevation myocardial infarction: a meta-analysis of randomised trials[J]. Heart Lung Circ, 2015, 24（4）: 327-334.

[25]LEVINE G N, BATES E R, BLANKENSHIP J C, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the society for cardiovascular angiography and interventions[J]. Circulation, 2016, 133（11）: 1135-1147.

[26]中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南（2016）[J].中华心血管病杂志（Chin），2016，44（5）：382-400.

[27]ELLIS S G, KEREIAKES D J, METZGER D C, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease[J]. N Engl J Med, 2015, 373（20）: 1905-1915.

[28]CASSESE S, BYRNE R A, NDREPEPA G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials[J]. Lancet, 2016, 387（10018）: 537-544.

[29]LI J, ELRASHIDI M Y, FLAMMER A J, et al. Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice[J]. Eur Heart J, 2013, 34（18）: 1375-1383.

[30]SAVER J L, GOYAL M, BONAFE A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke[J]. N Engl J Med, 2015, 372（24）: 2285-2295.

[31]BERKHEMER O A, FRANSEN P S, BEUMER D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med, 2015, 372（1）: 11-20.

[32]GOYAL M, DEMCHUK A M, MENON B K, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke[J]. N Engl J Med, 2015, 372（11）: 1019-1030.

[33]CAMPBELL B C, MITCHELL P J, KLEINIG T J, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med, 2015, 372（11）: 1009-1018.

[34]JOVIN T G, CHAMORRO A, COBO E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke[J]. N Engl J Med, 2015, 372（24）: 2296-2306.

[35]RODRIGUES F B, NEVES J B, CALDEIRA D, et al. Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis[J]. BMJ, 2016, 353（i1754）: i1754.

[36]Group ATC. Efficacy and safety of very early mobilisation within 24h of stroke onset (AVERT）: a randomised controlled trial. [J]. Lancet, 2015, 386（9988）: 46-55.

[37]WANG Y, WANG Y, ZHAO X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med, 2013, 369（1）: 11-19.

[38]VIVIANI A C, BRIGUORI C, RONCARATI R, et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease[J]. JACC Cardiovasc Interv, 2013, 6（11）: 1166-1175.

[39]CANNON C P, HARRINGTON R A, JAMES S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO）: a randomised double-blind study[J]. Lancet, 2010, 375（9711）: 283-293.

[40]MEGA J L, BRAUNWALD E, WIVIOTT S D, et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 366（1）: 9-19.

[41]ALEXANDER J H, LOPES R D, JAMES S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome[J]. N Engl J Med, 2011, 365（8）: 699-708.

[42]ROBINSON J G, FARNIER M, KREMPF M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J]. N Engl J Med, 2015, 372（16）: 1489-1499.

[43]SABATINE M S, GIUGLIANO R P, WIVIOTT S D, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J]. N Engl J Med, 2015, 372（16）: 1500-1509.

[44]DAI X, DING Y, LIU Z, et al. Phosphorylation of C/EBP homologous protein (CHOP) by the AMP-activated protein kinase alpha 1 in macrophages promotes CHOP degradation and reduces injury-induced neointimal disruption in vivo[J]. Circulation Research, 2016, 119（10）: 1089-1100.

[45]VIOLA J R, LEMNITZER P, JANSEN Y, et al. Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice[J]. Circ Res, 2016, 119（9）: 1030-1038.

[46]王璐璐，王雁.阿司匹林抵抗与其分子生物学机制[J].中华老年心脑血管病杂志，2016，18（4）：431-433.

[47]BHATT D L. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? [J]. Jama the Journal of the American Medical Association, 2009, 302（8）: 896.

[48]GE X, HUANG S, GAO H, et al. miR-21-5p alleviates leakage of injured brain microvascular endothelial barrier in vitro through suppressing inflammation and apoptosis[J]. Brain Res, 2016, 1650: 31-40.

[49]CARLONI S, FAVRAIS G, SALIBA E, et al. Melatonin modulates neonatal brain inflammation through endoplasmic reticulum stress, autophagy, and miR-34a/silent information regulator 1 pathway[J]. J Pineal Res, 2016, 61（3）: 370-380.

[50]YIN K J, DENG Z, HUANG H, et al. MiR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia[J]. Neurobiol Dis, 2010, 38（1）: 17-26.

[51]REN Y, YANG H, BROWNING C, et al. Prevalence of depression in coronary heart disease in China: a systematic review and meta-analysis[J]. Chin Med J (Engl）, 2014, 127（16）: 2991-2998.

[52]GUM P A, KOTTKE-MARCHANT K, WELSH P A, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease[J]. J Am Coll Cardiol, 2003, 41（6）: 961-965.

[53]SEREBRUANY V L, STEINHUBL S R, BERGER P B, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals[J]. J Am Coll Cardiol, 2005, 45（2）: 246-251.

[54]MULLER I, BESTA F, SCHULZ C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement[J]. Thromb Haemost, 2003, 89（5）: 783-787.

[55]LEPANTALO A, VIRTANEN K S, HEIKKILA J, et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions[J]. Eur Heart J, 2004, 25（6）: 476-483.

[56]SAMPSON U K, FAZIO S, LINTON M F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges[J]. Curr Atheroscler Rep, 2012, 14（1）: 1-10.

[57]PATEL M R, PETERSON E D, DAI D, et al. Low diagnostic yield of elective coronary angiography[J]. N Engl J Med, 2010, 362（10）: 886-895.

[58]DOUGLAS P S, PATEL M R, BAILEY S R, et al. Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography[J]. J Am Coll Cardiol, 2011, 58（8）: 801-809.

[59]ARBUSTINI E, GRASSO M, DIEGOLI M, et al. Coronary atherosclerotic plaques with and without thrombus in ischemic heart syndromes: a morphologic, immunohistochemical, and biochemical study[J]. Am J Cardiol, 1991, 68（7）: 36B-50B.

[60]HOCHMAN J S, TAMIS J E, THOMPSON T D, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global use of strategies to open occluded coronary arteries in acute coronary syndromes Ⅱ b investigators[J]. N Engl J Med, 1999, 341（4）: 226-232.

[61]BODEN W E, O'ROURKE R A, TEO K K, et al. Optimal medical therapy with or without PCI for stable coronary disease[J]. N Engl J Med, 2007, 356（15）: 1503-1516.

[62]ULUCAY A, DEMIRBAG R, YILMAZ R, et al. The relationship between plasma C-reactive protein levels and presence and severity of coronary stenosis in patients with stable angina[J]. Angiology, 2007, 58（6）: 657-662.

[63]PIRRO M, BERGERON J, DAGENAIS G R, et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men[J]. Arch Intern Med, 2001, 161（20）: 2474-2480.

[64]MARZILLI M, MERZ C N, BODEN W E, et al. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! [J]. Journal of the American College of Cardiology, 2012, 60（11）: 951-956.

[65]NADERI S H, BESTWICK J P, WALD D S. Adherence to drugs that prevent cardiovascular disease: metaanalysis on 376, 162 patients[J]. American Journal of Medicine, 2012, 125（9）: 882.

[66]CASTELLANO J M, SANZ G, PENALVO J L, et al. A polypill strategy to improve adherence: results from the FOCUS project[J]. J Am Coll Cardiol, 2014, 64（20）: 2071-2082.

[67]WALD N J, LAW M R. A strategy to reduce cardiovascular disease by more than 80%[J]. BMJ, 2003, 326（7404）: 1419.

[68]YUSUF S, HAWKEN S, OUNPUU S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study）: case-control study[J]. Lancet, 2004, 364（9438）: 937-952.

[69]EZZATI M, HOORN S V, RODGERS A, et al. Estimates of global and regional potential health gains from reducing multiple major risk factors[J]. Lancet, 2003, 362（9380）: 271-280.

[70]BANDOSZ P, O'FLAHERTY M, DRYGAS W, et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study[J]. BMJ, 2012, 344（7842）: d8136.

[71]FORD E S, AJANI U A, CROFT J B, et al. Explaining the decrease in U. S. deaths from coronary disease, 1980-2000. [J]. New England Journal of Medicine, 2007, 356（23）: 2388.

[72]LAATIKAINEN T, CRITCHLEY J, VARTIAINEN E, et al. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997[J]. Am J Epidemiol, 2005, 162（8）: 764-773.

[73]World Health Organization. Global Observatory for eHealth series-Volume 3: New horizons for health through mobile technologie[EB/OL]. (2011-06-07）［2020-03-15］. http://www.who.int/goe/publications/ ehealth_series_vol3/en/

[74]MARGOLIS K L, ASCHE S E, BERGDALL A R, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial[J]. JAMA, 2013, 310（1）: 46-56.

[75]CHOW C K, REDFERN J, HILLIS G S, et al. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial[J]. JAMA, 2015, 314（12）: 1255-1263.

[76]TIAN M, AJAY V S, DUNZHU D, et al. A cluster-randomized, controlled trial of a simplified multifaceted management program for individuals at high cardiovascular risk (SimCard trial) in rural Tibet, China, and Haryana, India[J]. Circulation, 2015, 132（9）: 815-824.

[77]HAMINE S, GERTH-GUYETTE E, FAULX D, et al. Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review[J]. J Med Internet Res, 2015, 17（2）: e52.

[78]AGEWALL S, BELTRAME J F, REYNOLDS H R, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries[J]. European Heart Journal, 2017, 38（3）: 143-153.

[79]文川，徐浩，黄启福，等.6种活血中药及芎芍胶囊对ApoE基因缺陷小鼠动脉粥样硬化斑块胶原沉积及其代谢的影响[J].中国病理生理杂志，2005，21（8）：1640.

[80]ZHOU X, MENCHE J, BARABASI A L, et al. Human symptoms-disease network[J]. Nat Commun, 2014, 5: 4212-4221.